Accounts Receivable, after Allowance for Credit Loss, Current in USD of Estrella Immunopharma, Inc. for Q2 2023

Taxonomy & unit: us-gaap: USD
Description: Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary: Estrella Immunopharma, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and change rate for Q2 2023.
Estrella Immunopharma, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 30 Jun 2023 was $273,066.
Source SEC data: View on sec.gov

Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)

Estrella Immunopharma, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q2 2023	$273,066			30 Jun 2023	10-Q	20 Nov 2023	2024	Q1

* An asterisk sign (*) next to the value indicates that the value is likely invalid.